GlassScriptPhysician profile
Michael A Reale
NPI 1992774434
$2,365.53
in general payments reported to CMS, 2019-2025
39 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,308 · 2020: $630 · 2021: $184 · 2022: $244.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $421.25 | 2019-2020 | |
| Novocure Gmbh | $200.00 | 2022 | |
| Glaxosmithkline, LLC. | $135.00 | 2021 | |
| Merck Sharp & Dohme LLC | $112.08 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $111.32 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $109.12 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $107.81 | 2019-2022 | |
| Comsort, INC | $100.00 | 2019 | |
| Amgen INC. | $88.00 | 2019-2020 | |
| Genentech USA, INC. | $83.50 | 2019 | |
| Janssen Biotech, INC. | $80.43 | 2019-2020 | |
| Pfizer INC. | $78.90 | 2019-2020 | |
| Incyte Corporation | $59.78 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $59.69 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $59.19 | 2019-2020 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $57.24 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $48.49 | 2019-2022 | |
| Seagen INC. | $40.07 | 2019 | |
| Karyopharm Therapeutics INC. | $37.11 | 2021 | |
| Genzyme Corporation | $30.27 | 2019 | |
| Celgene Corporation | $29.24 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.10 | 2019 | |
| Astellas Pharma US INC | $28.69 | 2019 | |
| Gilead Sciences, INC. | $27.87 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $25.50 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $24.25 | 2019 | |
| Tesaro, INC. | $23.07 | 2019 | |
| Alexion Pharmaceuticals, INC. | $19.69 | 2019 | |
| Amag Pharmaceuticals, INC. | $17.22 | 2019 | |
| Kyowa Kirin, INC. | $14.89 | 2020 | |
| Fortovia Therapeutics, INC. | $14.88 | 2019 | |
| Eisai INC. | $14.67 | 2019 | |
| Array Biopharma INC | $14.61 | 2019 | |
| Puma Biotechnology, INC. | $14.43 | 2019 | |
| Heron Therapeutics, INC. | $14.39 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $11.70 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.51 | 2019 | |
| Emd Serono, INC. | $10.57 | 2019 |
1 company reported research payments only; those appear in the research section below.
Research and ownership
$54,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Reale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.